antagonists targeting the CB1 receptor, such as agents being developed to treat obesity, have been associated with such central side effects as negative mood and depression. Furthermore, cannabinoid agonists targeting CB1 receptors, including candidates being developed for pain relief, have demonstrated the potential for abuse. By acting selectively at the periphery rather than in the CNS, the CeNeRx cannabinoid compounds have the potential for good therapeutic efficacy without these adverse effects.
Mr. Brand added, "Issuance of this new patent also reinforces the ongoing value of our collaboration with our discovery partner PharmaNess, who played a central role in identifying the structure-activity relationship of this series and in running key preclinical models that validated the role of these compounds in a range of conditions including glaucoma, pain, obesity and spasticity. We look forward to continuing to collaborate with them on this and potentially other programs."
CeNeRx obtained exclusive worldwide rights to develop, manufacture and commercialize its cannabinoid compounds from PharmaNess Neuroscience in Italy. The collaboration between CeNeRx and PharmaNess also includes drug discovery efforts aimed at further expanding the cannabinoid portfolio. CeNeRx has market exclusivity for the cannabinoid series of compounds beyond 2025.
The new patent, US 7,485,730 B2 issued on February 3, 2009.
About CeNeRx BioPharma
CeNeRx is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company's C
Page: 1 2 3 Related biology technology :1
|SOURCE CeNeRx BioPharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. CeNeRx BioPharma Completes $15 Million Series B Financing2
. DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments3
. Maryland Business, Academic and Biopharma Groups Underscore Commitment to Medical Innovation, Finding Cures and Supporting the Economy4
. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan5
. Helix BioPharma Announces Q2 2009 Financial Results6
. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers7
. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions8
. DOR BioPharma Appoints Gregg Lapointe, CPA, MBA, to its Board of Directors9
. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio10
. DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer11
. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results